Clinical trial
Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion
NCT00190788 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190788 |
|---|---|
| Title | Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion |
| Official title | A Phase IIIb Study to Determine Efficacy and Safety of Extended Drotrecogin Alfa (Activated) Therapy in Patients With Persistent Requirement for Vasopressor Support After 96 Hour Infusion With Commercial Drotrecogin Alfa (Activated) |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sepsis, Hypotension |
| Intervention type | Drug |
| Interventions | Drotrecogin Alfa (Activated), placebo |
| Enrollment | 200 |
| Start date | Jun 1, 2004 |
| Completion | May 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Oct 12, 2007 |
| Countries | France, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: